Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …

…, O Molinier, R Corre, I Monnet, V Gounant… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

…, A Lusque, N Meyer, V Gounant… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

[HTML][HTML] A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with …

…, D Carmier, J Madelaine, J Otto, V Gounant… - Journal of Thoracic …, 2019 - Elsevier
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

…, A Cazes, C Danel, B Abbar, J Pluvy, V Gounant… - Lung cancer, 2019 - Elsevier
Introduction Tumor mutational burden (TMB) correlates with response to immune checkpoint
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …

[HTML][HTML] Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article

…, D Re, Z Adjtoutah, B Seitz-Polski, V Gounant… - European Journal of …, 2022 - Elsevier
Taking into account higher risk of severe coronavirus disease 2019 or death among patients
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …

[HTML][HTML] Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients …

V Gounant, VM Ferré, G Soussi, C Charpentier… - Journal of Thoracic …, 2022 - Elsevier
Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …

[HTML][HTML] Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma

…, I Monnet, J Mazières, F Barlesi, V Gounant… - Journal of Thoracic …, 2020 - Elsevier
Introduction Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …

Six-month prognosis of patients with lung cancer admitted to the intensive care unit

…, A Parrot, A Lavole, PY Ancel, V Gounant… - Intensive care …, 2009 - Springer
Background Intensive care unit (ICU) admission of patients with lung cancer remains
debated because of the poor short-term prognosis. However, ICU admission of such patients …

[HTML][HTML] Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry

…, G Rossi, A Schrock, S Ali, V Gounant… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Although NRG1 fusions are oncogenic drivers across multiple tumor types
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study

…, R Lacave, A Pujals, N Girard, C Callens, V Gounant… - Lung Cancer, 2019 - Elsevier
Objectives The understanding of histo-molecular mechanisms associated with resistance to
osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-…